New hope for tough cancers: first patients test novel drug
NCT ID NCT05957081
Summary
This is the first study in people to test a new immunotherapy drug called PMC-309. It aims to see if the drug is safe and how the body processes it when given alone or with another cancer drug, pembrolizumab. The study is for adults with advanced solid tumors that have spread or cannot be removed by surgery and have stopped responding to prior treatments, including other immunotherapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Alfred Health
RECRUITINGMelbourne, Victoria, 3004, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Australian Hospital Care (Pindara) PTY LTD. Trading as Pindara Private Hospital
RECRUITINGBenowa, Queensland, 4217, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ballarat Regional Integrated Cancer Centre (Grampians Health)
RECRUITINGBallarat, Victoria, 3350, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cabrini Health Limited
RECRUITINGMalvern, Victoria, 3144, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.